Brain neuropeptidergic function in suicide victims

Human Psychopharmacology

Volumn 11, Issue 6, 1996, Pages 451-461

  Arranz, Belén ^a,b   Blennow, Kaj ^c   Ekman, Rolf ^c   Eriksson, Anders ^d   Marcusson, Jan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

corticotropin releasing factor; human brain; neuropeptide Y; somatostatin; suicide

Indexed keywords

CARBON MONOXIDE; CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE; SOMATOSTATIN;

ADULT; ARTICLE; BEHAVIOR; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; INTOXICATION; MALE; PRIORITY JOURNAL; SUICIDE;

EID: 0030458747     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-1077(199611)11:6<451::aid-hup812>3.0.co;2-%23     Document Type: Article

References (67)

1. Ågren, H. and Lundqvist, G. (1984). Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology, 9, 233-248.
2. American Psychiatric Association. (1987). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. American Psychiatric Association, Washington DC.
3. Aponte, G., Leung, P., Gross, D. and Yamada, T. (1984). Effects of somatostatin on food intake in rats. Life Sciences, 35, 741-746.
4. Arató, M., Banki, C. M., Bissette, G. and Nemeroff, C. B. (1989). Elevated CSF CRF in suicide victims. Biological Psychiatry, 25, 355-359.
5. Arai, H., Moroji, T. and Kosaka, K. (1984). Somatostatin and vasoactive intestinal polypeptide in post-mortem brains from patients with Alzheimer-type dementia. Neuroscience Letters, 53, 73-78.
6. Arranz, B., Blennow, K., Ekman, R., Eriksson, A., Mansson, J. E. and Marcusson, J. (1996). Brain monoaminergic and neuropeptidergic variations in human aging. Journal of Neural Transmission (General Section), 103, 101-115.
7. Axelrod, J. and Reisine, D. (1984). Cerebrospinal fluid corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. American Journal of Psychiatry, 144, 873-877.
8. Banki, C. M., Bissette, G., Nemeroff, C. B. and Arató, M. (1988). Corticotropin-releasing factor in depression and suicide. In: Current Issues of Suicidology, Möller, J. H., Schmidtke, A. and Welz, R. (Eds), Springer, Berlin, pp. 247-251.
9. Barraclough, B. M., Bunch, J., Nelson, B. and Sainsbury, P. (1974). A hundred cases of suicide: clinical aspects. British Journal of Psychiatry, 125, 355-373.
10. Beal, M. F., Growdon, J. H., Mazurek, M. F. and Martin, J. B. (1986). CSF somatostatin-like immunoreactivity in dementia. Neurology, 36, 294-297.
11. Beal, M. F., Mazurek, M. F., Black, P. M. and Martin, J. B. (1985). Human cerebrospinal fluid somatostatin in neurologic disease. Journal of Neurological Sciences, 71, 91-104.
12. Berretini, W. H., Doran, A., Kelsoe, J., Roy, A. and Pickar, D. (1987). Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology, 1, 81-83.
13. Bissette, G., Widerlöv, E., Walléus, H., Karlsson, I., Eklund, K., Forsman, A. and Nemeroff, C. B. (1986). Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in neuropsychiatric disorders. Archives of General Psychiatry, 43, 1148-1151.
14. Black, P. M., Ballantine, H. T. Jr., Carr, D. B., Beal, M. F. and Martin, J. B. (1986). Beta-endorphin and somatostatin concentrations in the ventricular cerebrospinal fluid of patients with affective disorder. Biological Psychiatry, 21, 1077-1081.
15. Black, D. W., Warrack, G. and Winokur, G. (1985). The Iowa-record linkage study. I. Suicides and accidental deaths among psychiatric patients. Archives of General Psychiatry, 42, 71-75.
16. Britton, K. T., Lee, G., Dana, R., Risch, S. C. and Koob, G. F. (1986). Activating and 'axiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. Life Sciences, 39, 1281-1286.
17. Bunney, W. E. Jr. and Davis, J. M. (1965). Norepinephrine in depressive reactions: A review. Archives of General Psychiatry, 13, 483-494.
18. Butler, P. D., Weiss, J. M., Stout, J. C. and Nemeroff, C. B. (1990). Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. Journal of Neurosciences, 10, 176-183.
19. Candy, J. M., Gascoigne, A. D. and Biggins, J. A. (1985). Somatostatin immunoreactivity in cortical and subcortical regions in Alzheimer's disease. Journal of Neurological Sciences, 71, 315-323.
20. Chaouloff, F. (1993) Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Research Reviews, 18, 1-32.
21. Charlton, B. G., Wright, C., Leake, A., Ferrier, I. N., Cheetham, S. C. and Katona, C. L. E. (1988). Somatostatin immunoreactivity in postmortem brain from depressed suicides. Archives of General Psychiatry, 45, 597-597.
22. Danguir, J. (1986). Intracerebroventricular infusion of Somatostatin selectively increases paradoxical sleep in rats. Brain Research, 367, 26-30.
23. Davies, P. and Terry, R. D. (1981). Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiology, 2, 9-14.
24. Davis, K. L., Davidson, M., Yang, R. T., Davis, B. M., Siever, L. J., Mohs, R. C., Ryan, T., Coccaro, E., Bierer, L. and Targum, S. D. (1988). CSF somatostatin in Alzheimer's disease, depressed patients, and controls. Biological Psychiatry, 24, 710-712.
25. DeSouza, E. B., Whitehouse, P. J., Kuhar, M. J., Price, D. L. and Vale, W. W. (1986). Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature, 319, 593-595.
26. Dupont, E., Christensen, S. E. and Hansen, A. P. (1982). Low cerebrospinal fluid somatostatin in Parkinson's disease: an irreversible abnormality. Neurology, 32, 312-314.
27. Edvinsson, L., Ekman, R. and Thulin, T. (1991). Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regulatory Peptides, 32, 279-287.
28. Ehlers, C., Henriksen, S. and Wang, M. (1983). Corticotropin-releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Research, 278, 332-336.
29. Ekman, R., Servenius, B , Castro, M. G., Lowry, P. J., Cederlund, A. S., Bergman, O. and Sjögren, H. O. (1993). Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes. Journal of Neuroimmunology, 44, 7-14.
30. Ekman, R., Wahlestedt, C., Böttcher, G., Sundler, F., Håkanson, R. and Panula, P. (1986). Peptide YY-like immunoreactivity in the central nervous system of the rat. Regulatory Peptides, 16, 157-168.
31. Epelbaum, J., Ruberg, M. and Moyse, E. (1983). Somatostatin and dementia in Parkinson's disease. Brain Research, 278, 376-379.
32. Evans, D. L. and Nemeroff, C. B. (1987). The clinical use of the dexamethasone suppression test in DSM-III affective disorders: correlation with the severe depressive subtypes of melancholia and psychosis. Journal of Psychiatry Research, 21, 185-194.
33. France, R. D., Urban, B., Krishnan, K., R., Bissette, G., Banki, C. M., Nemeroff, C. and Speilman, F. J. (1988). CSF corticotrophin-releasing factor-like immunoactivity in chronic pain patients with and without major depression. Biological Psychiatry, 23, 86-88.
34. Gerner, R. H. and Yamada, T. (1982). Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Research, 238, 292-302.
35. Heilig, M. (1993). Neuropeptide Y in relation to behavior and psychiatric disorders. In: The Biology of Neuropeptide Y and Related Peptides, Colmers, W. F. and Wahlestedt, C. (Eds), Humana Press Inc, Totowa NJ, pp. 511-554.
36. Heilig, M. and Widerlöv, E. (1990). Neuropeptide Y: an overview of central distribution, functional aspects and possible involvement in neuropsychiatric illnesses. Acta Psychiatrica Scandinavica, 82, 95-114.
37. Holmes, M. C., DiRenzo, G., Bechfood, U., Billham, B. and Jones, M. T. (1982). Role of serotonin in the control of secretion of corticotropin releasing factor. Journal of Endocrinology, 93, 151-160.
38. Levine, A. S., Rogers, B. and Kneup, J. (1983). Effects of centrally administered corticotropin-releasing factor (CRF) on multiple feeding paradigms. Life Sciences, 22, 337-339.
39. McLean, P. D. (1955). The limbic system ('visceral brain') and emotional behaviour. Archives of Neurological Psychiatry, 73, 130-134.
40. Nemeroff, C. B., and Bissette, G. (1986). Neuropeptides in psychiatric disorders. In: American Handbook of Psychiatry, Berger, P. A. and Brodie, H. K. H. (Eds), Basic Books, New York, pp. 64-110.
41. Nemeroff, C. B., Owens, M. J., Bissette, G., Andorn, A. C. and Stanley, M. (1988). Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Archives of General Psychiatry, 45, 577-579.
42. Nemeroff, C. B., Widerlöv, E., Bissette, G., Walleuss, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T. and Vale, W. (1984). Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science, 226, 1342-1344.
43. Nemeroff, C. B., Youngblood, W. W. and Manberg, P. J. (1983). Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science, 221, 972-975.
44. Norman, W. H., Brown, W. A., Miller, I. W., Keitnar, G. I. and Overholser, J. C. (1990). The dexamethasone suppression test and completed suicide. Acta Psychiatrica Scandinavica, 81, 120-125.
45. Owens, M. J., Stanley, M., Bissette, G. and Nemeroff, C. B. (1986). CRF receptor number is decreased in the frontal cortex of suicide victims. Proceedings of the American College of Neuropsychopharmacology, 25, 189.
46. de Quidt, M. E. and Emson, P. C. (1986). Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system - I. Radioimmunoassay and cromatographic characterization. Neuroscience, 18, 527-543.
47. Reichlin, S. (1983). Somatostatin. In: Brain Peptides, Krieger, D. T., Brownstein, M. J. and Martin, J. B. (Eds), Wiley, New York, pp. 711-752.
48. Rezek, M., Havlicek, V. and Hughes, K. R. (1977). Behavioral and motor excitation and inhibition induced by the administration of small and large doses of somatostatin into the amygdala. Neuropharmacology, 16, 157-162.
49. Risch, S. C., Lewine, R. J. and Jewart, R. D. (1991). Relationship between cerebrospinal fluid peptides and neurotransmitters in depression. In: Central Nervous System Peptide Mechanisms in Stress and Depression, Risch, S. C. (Ed.), American Psychiatric Press, Washington DC, pp. 93-103.
50. Rubinow, D. R. (1986). Cerebrospinal fluid somatostatin and psychiatric illness. Biological Psychiatry, 21, 341-365.
51. Rubinow, D. R., Gold, P. W., Post, R. M., Ballenger, J. C., Cowdry, R., Bollinger, J. and Reichlin, S. (1983). CSF somatostatin in affective illness. Archives in General Psychiatry, 40, 409-412.
52. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, 122, 509-522.
53. Siever, L. J. and Davies, K. L. (1985). Overview: towards a dysregulation hypothesis of depression. American Journal of Psychiatry, 142, 1017-1031.
54. Sirinathsinghji, D. J. S., Rees, L. H. and Rivier, J. (1983). Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature, 305, 232-235.
55. Sunderland, T., Rubinow, D. R., Tariot, P. N., Cohen, R. M., Newhouse, P. A., Mellow, A. M., Mueller, E. A. and Murphy, D. L. (1987). CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. American Journal of Psychiatry, 144, 1313-1316.
56. Thompson, W. D., Orvaschel, Prusoff, B. A. and Kidd, K. K. (1982). An evaluation of the family history method for ascertaining psychiatric disorders. Archives of General Psychiatry, 39, 53-59.
57. Träskman-Bendz, L., Ekman, R., Regnéll, G. and Öhmann, R. (1992). HPA-related CSF neuropeptides in suicide attempters. European Neuropsychopharmacology, 2, 99-106.
58. Van Praag, H. M. (1986). Biological suicide research: Outcome and limitations. Biological Psychiatry, 21, 1305-1323.
59. Vecsei, L., Kiraly, C. and Bollok, I. (1984). Comparative studies with somatostatin and cysteamine in different behavior tests on rats. Pharmacological and Biochemical Behavior, 21, 833-837.
60. Wahlestedt, C., Ekman, R. and Widerlöv, E. (1989). Neuropeptide Y (NPY) and the central nervous system: distribution, effects and possible relationship to neurological and psychiatric disorders. Progress in Neuropsychopharmacology and Biological Psychiatry, 13, 31-54.
61. Wallengren, J., Ekman, R. and Sundler, F. (1987). Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Dermato-Venereological, 67, 185-192.
62. Widdowson, P. S., Ordway, G. A. and Halaris, A. E. (1992). Reduced neuropeptide Y concentrations in suicide brain. Journal of Neurochemistry, 59, 73-80.
63. Widerlöv, E., Bissette, G. and Nemeroff, C. B. (1988a). Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. Journal of Affective Disorders, 14, 99-107.
64. Widerlöv, E., Lindström, L. H., Wahlestedt, C. and Ekman, R. (1988b). Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. Journal of Psychiatry Research, 22, 69-79.
65. Widerlöv, E., Heilig, M., Ekman, R. and Wahlestedt, C. (1989). Neuropeptide Y: possible involvement in depression and anxiety. In: Nobel Conference on NPY, Mutt, V., Fuxe, K., Hökfelt, T. and Lundberg, J. (Eds), Raven Press, New York, pp. 331-342.
66. Wolkowitz, O. M., Rubinow, D. R., Breier, A., Doran, A. R., Davis, C. and Pickar, D. (1987). Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness. Life Sciences, 41, 1929-1933.
67. Wood, P. L., Etienne, P. and Lal, S. (1982). Reduced lumbar CSF somatostatin in Alzheimer's disease. Life Sciences, 31, 2073-2079.